Intervention: Pembrolizumab coformulated with berahyaluronidase alfa
Found 7 matching trials
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
PHASE3
This study is to assess the pharmacokinetics (PK) and safety of SC pembroli...
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
PHASE2
The purpose of this study is to evaluate participant preference for coformu...
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
PHASE3
This study is to assess the pharmacokinetics (PK) and safety of SC pembroli...
Status
Active Not Recruiting
Location
St. Joseph's Hospital and Medical Center-Dignity Health Cancer Institute ( Site 0023)
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
PHASE3
Researchers are looking for new ways to treat high-risk, localized non-smal...
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)
PHASE2
The primary purpose of the study is to assess the pharmacokinetics (PK) pro...
Status
Active Not Recruiting
Location
University of Iowa-Holden Comprehensive Cancer Center ( Site 0115)